Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
|
| |
|
Date of report (date of earliest event reported): January 11, 2019 (January 11, 2019) |
CUMBERLAND PHARMACEUTICALS INC.
__________________________________________
(Exact name of registrant as specified in its charter)
|
| | | |
| | |
| | Tennessee | 001-33637 | 62-1765329 |
| | (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| |
| | | | |
| | 2525 West End Avenue, Suite 950, Nashville, Tennessee 37203 |
| | (Address of principal executive offices) (Zip Code) |
| | | |
| | (615) 255-0068 |
| | Registrant's telephone number, including area code: |
Not Applicable
____________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01 Other Events
On January 4, 2019, the U.S. Food and Drug Administration ("FDA") accepted for review the New Drug Application ("NDA") for the approval of our methotrexate product line, which is designed to treat adult and pediatric patients with arthritis and adults with psoriasis. The NDA was accepted for filing with a PDUFA action date projected for November 2019.
The application was submitted to the FDA in November 2018 and its submission follows two meetings held with the FDA to discuss the approval pathway and requirements for the submission. We remitted a payment of $1.3 million to the FDA for the PDUFA Application Fee associated with this methotrexate product line application.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | |
| |
| | |
| | Cumberland Pharmaceuticals Inc. |
| | |
| Dated: January 11, 2019 | By: /s/ Michael Bonner |
| | |
| | Name: Michael Bonner |
| | Title: Chief Financial Officer |
| | |